MASSTRPLAN is a multidisciplinary network of 6 academic beneficiaries, 2 hospital beneficiaries and 2 commercial beneficiaries, collaborating with 15 partners (technology, pharmaceuticals & life science-related industries, hospital & academic teams, and learned societies). Its focus is on “Lipoxidation”, which means the modification of proteins by reactive lipid oxidation products. Oxidative modifications and lipoxidation of proteins occur in inflammatory diseases, leading to cellular dysfunction and disease pathology; the development of improved mass spectrometry approaches will enable them to be analysed more efficiently.
MASSTRPLAN will train 14 Early Stage Researchers (ESRs) in translational science centred on advanced analytical techniques to detect oxidized phospholipids & proteins in biological & clinical samples, evaluate their biochemical roles, and develop new diagnostic tools for commercialization.
MASSTRPLAN is funded by the European Commission’s REA with the H2020 MSCA with a total budget of €3.5 million. The project started on the 1st October 2015 and will run for 4 years. Read more…